Press Releases

Date Title
8/31/23 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8/30/23 Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) Test
8/2/23 Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments
7/31/23 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
7/26/23 Sarepta Therapeutics to Announce Second Quarter 2023 Financial Results
7/5/23 Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million
7/3/23 Sarepta Therapeutics to Present at Cowen's 2nd Annual RNA Therapeutics Summit
6/30/23 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6/22/23 Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy
5/31/23 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Displaying 11 - 20 of 795